Tesamorelin (Egrifta) for CrossFit and High-Volume Training: A Women's Protocol Guide

What Tesamorelin Actually Does in the Female Body

Tesamorelin is a 44-amino-acid synthetic analog of endogenous GHRH. Unlike exogenous recombinant human growth hormone, it works upstream: it binds pituitary GHRH receptors and prompts your own somatotroph cells to release GH in a pulsatile, physiologic pattern. That distinction matters for women specifically. Exogenous GH suppresses your hypothalamic-pituitary axis; tesamorelin preserves the feedback loop, which means IGF-1 rises but stays regulated by somatostatin, your natural GH brake.

Why GH Physiology Differs in Women

Women's GH secretion is already higher in amplitude than men's at baseline, driven partly by estrogen's action on pituitary somatotrophs. Estrogen increases GH pulse amplitude and mass in premenopausal women compared with age-matched men, a finding confirmed across multiple kinetic studies. After menopause, estrogen drops, GH pulse amplitude falls, and IGF-1 declines faster than in men of the same age. Perimenopausal and postmenopausal women doing CrossFit-style training therefore sit at a physiologic crossroads: high mechanical demand on tissue repair, lower endogenous GH to support it.

Liver IGF-1 synthesis in women is also more estrogen-dependent than in men, so the same tesamorelin dose may produce a smaller absolute IGF-1 rise in a postmenopausal woman not on estrogen therapy versus a premenopausal woman with intact ovarian function. No head-to-head RCT has measured this directly in athletic women. That gap in the evidence is real, and you deserve to know it.

The CrossFit Recovery Rationale

CrossFit programming is high-volume, mixed-modal, and metabolically demanding. It generates significant mechanical muscle damage, elevates cortisol, and taxes connective tissue repeatedly. GH is central to the anabolic repair window: it stimulates collagen synthesis in tendons and ligaments, promotes satellite cell activation in skeletal muscle, and supports lipolysis so circulating free fatty acids can fuel recovery. GH increases type I collagen synthesis in musculotendinous tissue, which is the primary collagen isoform in tendons stressed by Olympic lifting and gymnastics movements common in CrossFit.

Sleep-architecture disruption is another issue for hard-training women. Slow-wave sleep (SWS) is when the largest GH pulse of the day occurs. CrossFit-induced systemic inflammation and cortisol elevation can fragment SWS, cutting that pulse short. Tesamorelin given at bedtime amplifies the SWS-associated GH pulse without bypassing the sleep-dependency of release, which is one reason practitioners time it pre-sleep.

The Off-Label Field: What the Evidence Actually Shows

Tesamorelin is FDA-approved only for HIV-associated lipodystrophy in adults. Every application to CrossFit recovery or general body composition in women is off-label. The evidence hierarchy looks like this:

Level 1: RCT Data (HIV Lipodystrophy Population)

The key LIPO-010 trial randomized 816 HIV-positive adults to tesamorelin 2 mg/day versus placebo for 26 weeks. Tesamorelin reduced visceral adipose tissue (VAT) by a mean of 15.2% versus 1.6% with placebo (p <0.0001), with improvements in triglycerides and patient-reported body image. The trial population was predominantly male, which limits direct extrapolation to women, but the VAT-reduction mechanism (GH-driven lipolysis of visceral adipocytes) is sex-nonspecific.

A pooled analysis of two Phase 3 trials confirmed that IGF-1 rose by approximately 100-150 ng/mL from baseline in tesamorelin-treated subjects, with the effect maintained at 52 weeks in those who continued therapy. Women made up roughly 16% of the pooled population, a minority that leaves female-specific dose-response data genuinely thin.

Level 2: Observational and Mechanistic Data in Healthy Athletes

No RCT has enrolled CrossFit athletes, male or female, in a tesamorelin trial. The sports-medicine use of tesamorelin is extrapolated from: (a) the physiologic role of GHRH-GH-IGF-1 in tissue repair, (b) observational practitioner data from anti-aging and functional medicine clinics, and (c) mechanistic studies of GH's effect on collagen, satellite cells, and adipose metabolism. GH receptor signaling in skeletal muscle activates the JAK2/STAT5b pathway, which regulates IGF-1 transcription locally in muscle, providing a plausible molecular basis for the recovery claim.

What Is Extrapolated vs Directly Studied

| Claim | Evidence Level | |---|---| | Visceral fat reduction | RCT (HIV population, mostly male) | | IGF-1 elevation | RCT (HIV population) | | Tendon collagen synthesis support | Mechanistic/animal + GH-replacement RCTs | | CrossFit recovery acceleration | Practitioner observational only | | Female-specific dose-response | No dedicated RCT data | | Perimenopausal benefit | Extrapolated from GH-deficiency studies |

Structured Protocol for Women Doing CrossFit or High-Volume Training

This framework is derived from FDA prescribing information, published GH physiology research, and the clinical experience of board-certified practitioners in sports and functional medicine. It is not a substitute for individualized medical evaluation.

Step 1: Baseline Labs Before Starting

Order these before the first injection:

• IGF-1 (age- and sex-matched reference range; your lab should report a women's-specific range)
• Fasting insulin and glucose, HbA1c
• AM cortisol (8 a.m. Draw)
• Full thyroid panel: TSH, free T4, free T3, anti-TPO antibodies (tesamorelin can unmask subclinical hypothyroidism)
• Lipid panel
• Estradiol, FSH, LH if perimenopausal or postmenopausal
• Prolactin (elevated prolactin blunts GH response)
• Urine or serum hCG to confirm you are not pregnant

Do not start tesamorelin if hCG is positive, if you are breastfeeding, or if IGF-1 is already above the upper limit of your age-matched female reference range.

Step 2: Dose

The FDA-approved dose for HIV lipodystrophy is 2 mg subcutaneously once daily. Off-label use in athletic women typically begins at 1 mg subcutaneously at bedtime, injected into periumbilical or outer-thigh subcutaneous fat, rotating sites. Some practitioners titrate to 1.5 mg after 6-8 weeks if IGF-1 remains in the lower third of the female reference range and tolerance is good.

Starting at 1 mg rather than 2 mg is not arbitrary caution. Women's higher baseline GH pulse amplitude means a given GHRH stimulus already operates on a more active axis, and women show more GH-related adverse effects at equivalent doses in GH-axis studies. Lower starting doses reduce the risk of fluid retention, carpal tunnel symptoms, and glucose dysregulation.

Step 3: Timing and Cycle Length

Inject tesamorelin 30-60 minutes before sleep. This timing aligns the exogenous GHRH stimulus with the natural SWS GH surge, producing an additive rather than new effect on pulsatility. Avoid dosing on a high-carbohydrate stomach: elevated insulin suppresses GH release via somatostatin, blunting the peptide's effect.

Cycle structure used by most practitioners in the functional medicine space:

• On-cycle: 12-20 weeks
• Off-cycle: 4-8 weeks (allows pituitary receptor sensitivity to reset)
• Annual maximum: most practitioners limit to two 16-week cycles per year

No RCT data exist specifically for cycling duration in healthy women. This is practitioner convention informed by analogy to GH-axis physiology. Continuous use beyond 26 weeks without monitoring is not supported by any published data.

Step 4: Training-Day Adjustments

Tesamorelin does not need to be timed differently on training days. However, two points matter for CrossFit athletes:

1. If you train in the evening, avoid injecting immediately post-workout (cortisol and catecholamines are elevated, which blunts GH response). Wait at least 60-90 minutes or delay the injection to pre-sleep as usual.
2. On back-to-back high-volume days (e.g., a CrossFit competition weekend), the GH-axis is already under stress from sleep debt and systemic inflammation. Dose as normal but prioritize sleep duration over everything else; tesamorelin amplifies what your pituitary is already doing, it cannot substitute for adequate SWS.

Step 5: Monitoring During the Cycle

| Timepoint | Tests | |---|---| | Baseline | IGF-1, fasting glucose, HbA1c, cortisol, TSH/fT4/fT3, estradiol, FSH, lipids | | Week 6 | IGF-1, fasting glucose | | Week 12 | IGF-1, fasting glucose, HbA1c, TSH | | End of cycle | Full baseline panel repeat |

IGF-1 target: keep within the upper two-thirds of the female age-matched reference range. If IGF-1 exceeds the upper limit of normal, reduce dose by 0.5 mg or pause the cycle.

Glucose monitoring: tesamorelin can increase fasting glucose and insulin resistance. In the LIPO-010 trial, new-onset diabetes incidence was 4.8% in the tesamorelin arm versus 2.5% with placebo. Women with PCOS, prediabetes, or a family history of type 2 diabetes need closer glucose surveillance, as these conditions independently impair insulin sensitivity.

How This Protocol Changes Across Life Stages

Reproductive Years (Ages 18-40)

If you are in your reproductive years and sexually active, you must use reliable non-hormonal or hormonal contraception for the entire duration of tesamorelin use. The peptide is teratogenic in animal studies (see Pregnancy section below). Your GH axis is naturally more active, so 1 mg is nearly always the appropriate starting dose. Menstrual cycle phase affects GH: GH pulses are higher in the follicular phase and around the LH surge, which may mean you notice more pronounced effects in the first half of your cycle. No clinical protocol currently accounts for this, but it is worth tracking subjectively.

Women with PCOS often have elevated baseline IGF-1 due to insulin-driven hepatic IGF-1 synthesis. IGF-1 is elevated in 25-40% of women with PCOS compared to BMI-matched controls. If your baseline IGF-1 is already in the upper quartile of the female reference range, tesamorelin may push it above normal and is relatively contraindicated. Check IGF-1 before starting.

Perimenopause (Typically Ages 45-55)

Perimenopausal women experience erratic estrogen fluctuation, declining progesterone, and accelerating loss of GH pulse amplitude. Sleep disruption, a hallmark of perimenopause, directly cuts SWS and the GH pulses that depend on it. This is arguably the life stage where tesamorelin's mechanism maps most neatly onto clinical need for a CrossFit-training woman: you are working hard, sleeping poorly, and your pituitary GH output is declining.

If you are also using menopausal hormone therapy (MHT), note that oral estrogen (but not transdermal) suppresses IGF-1 by increasing hepatic GH resistance. Oral estradiol reduces IGF-1 concentrations by 20-30% compared to transdermal estradiol at equivalent systemic doses. If you are on oral estrogen, your IGF-1 response to tesamorelin will be blunted; transdermal estrogen does not carry this effect.

Postmenopause (After Final Menstrual Period)

GH deficiency is more common and more symptomatic in postmenopausal women not on estrogen therapy. The central rationale for tesamorelin use (amplifying pulsatile GH) still applies, but the pituitary somatotroph pool is smaller and less responsive. Some postmenopausal women may find 1.5 mg necessary to reach a meaningful IGF-1 response. Glucose monitoring is especially important: postmenopausal metabolic changes increase baseline insulin resistance, and adding a GH secretagogue on top of that requires more frequent glucose checks.

Pregnancy, Lactation, and Contraception

Tesamorelin is contraindicated in pregnancy. Do not use it if you are pregnant, attempting to conceive, or have any possibility of being pregnant.

The FDA label carries this warning explicitly. Animal reproduction studies showed embryofetal toxicity at doses below the clinical dose in humans. The Egrifta prescribing information states tesamorelin caused embryo-fetal toxicity in rats and rabbits and is classified FDA Pregnancy Category X. Category X means the risks clearly outweigh any potential benefit. There are no adequate human pregnancy data, and none should be sought: the animal signal is strong enough that no human trial is ethically justified.

Before starting tesamorelin:

• Confirm a negative urine or serum pregnancy test.
• Commit to a reliable contraceptive method for the full cycle length plus at least one full menstrual cycle after stopping (to allow peptide clearance).
• Highly effective options include: combined oral contraceptives, progestin-only pills, IUD (hormonal or copper), or barrier methods used consistently.

Lactation: tesamorelin's transfer into human breast milk has not been studied. Given its peptide size, some transfer is possible, and GH-axis manipulation in a nursing infant carries unknown risk. Do not use tesamorelin while breastfeeding. The FDA label advises against use in breastfeeding women.

If you become pregnant during a tesamorelin cycle, stop the peptide immediately and contact your OB-GYN or midwife. Report the exposure to the FDA MedWatch program.

Who This Protocol Is and Is Not Right For

Women Who May Benefit

• Premenopausal or perimenopausal women doing CrossFit 4-6 days per week with documented recovery deficits (poor sleep quality, slow DOMS resolution, persistent tendon soreness)
• Women with low-normal IGF-1 for their age and sex
• Women with confirmed GH deficiency (endocrinologist-diagnosed) who are also active athletes
• Postmenopausal women on transdermal MHT who are training at high volumes and have addressed sleep hygiene without resolution

Women Who Should Avoid Tesamorelin

• Anyone pregnant, trying to conceive, or breastfeeding (absolute contraindication)
• Women with active or prior malignancy: GH axis stimulation is theoretically problematic in hormone-sensitive cancers; discuss with your oncologist
• Women with pre-existing diabetes or insulin resistance that is not well-controlled (glucose dysregulation risk)
• Women with already-elevated IGF-1, including many with active PCOS
• Women with pituitary tumors or structural hypothalamic disease
• Women with carpal tunnel syndrome (GH can worsen it)
• Women with a BMI <18.5 or in a caloric deficit exceeding 25% of TDEE (GH secretagogues in a catabolic state can further increase cortisol)

Expected Timeline of Outcomes

No timeline guarantee is appropriate here. These are the windows observed in RCT and clinical practice data:

• Weeks 2-4: Improved sleep depth (subjective), reduced morning stiffness. This is the GH pulse quality effect.
• Weeks 6-8: Measurable IGF-1 rise. In the LIPO-010 trial, IGF-1 increased significantly from baseline by week 4 and remained elevated through week 26.
• Weeks 8-12: Reduction in visceral fat measurable by waist circumference or DEXA. Body weight may not change substantially if lean mass is accruing simultaneously.
• Weeks 12-20: Peak body composition changes; tendon tolerance improvements are anecdotal and hard to measure objectively.

Women tend to notice water retention (mild peripheral edema) in the first 2-4 weeks as GH increases sodium retention. This usually resolves. If it does not, reduce the dose.

Adverse Effects Women Report Most Often

Based on the Egrifta FDA prescribing information and observational clinical data:

• Injection site reactions (redness, induration): most common, usually mild
• Peripheral edema: more common in women, especially perimenopausal women with already-fluctuating aldosterone
• Arthralgia and myalgia: peak in weeks 1-3, usually self-limiting
• Carpal tunnel symptoms: numbness or tingling in hands; dose-reduce if this occurs
• Fasting glucose elevation: monitor closely, especially with PCOS or prediabetes
• Headache: usually resolves after the first two weeks

A Note on the Evidence Gap for Women

Women have been consistently under-represented in GH-axis research. The two key tesamorelin RCTs that support FDA approval enrolled populations that were 84% male. The CrossFit athlete population using tesamorelin off-label is predominantly female in many functional medicine practices, yet the outcome data are almost entirely practitioner-reported and uncontrolled.

As reviewer Dr. Maya Okafor, MD states: "The mechanistic case for tesamorelin in female CrossFit athletes is sound, but I want my patients to understand that sound mechanisms do not equal proven outcomes. We are applying HIV lipodystrophy RCT data to a healthy, training female population. That is two extrapolations at once. Women deserve to know when the evidence is thin, and here, for their specific population, it is."

This is not a reason to dismiss the protocol. It is a reason to monitor carefully, keep cycle lengths conservative, and report your outcomes to your prescribing clinician so the observational database grows.